CTI Life Sciences Fund L.P. — 2014 Investments
2 investments dated 2014 · listed companies and verified rows first · show all
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Board seatShermaine Tilley· per SEC Form D
Co-investorsBrace PharmaLumira VenturesNextech InvestWUTIF Capital
BiotechWaltham, US
Garry Nicholson(Executive Officer, Director)Edward Freedman(Executive Officer)Rakesh Jain(Director)
BoardRobert Langer(Director)David Mott(Director)Alan Crane(Director)
Co-investorsPolaris Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.